FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280492468> ?p ?o ?g. }

• W4280492468 abstract "Aims: To review the effects of bisphosphonates on bone density, fractures, and bone markers in osteopenic older women. Methods: Relevant articles published before February 2022 were searched in PubMed, EMBASE, and the Cochrane Library. All randomized controlled trials that reported incident fractures, bone mineral density (BMD), bone markers, or adverse events with bisphosphonates in osteopenic older women were included. The quality of included studies was assessed using the Cochrane Risk of Bias tool. The risk ratios (RRs) for fractures, net percent change in bone mineral density and differences in bone markers were calculated using a meta-analysis. Results: A total of 11 studies were included in our meta-analysis. Bisphosphonates significantly increased the percent changes in the lumbar spine BMD (WMD, 5.60; 95% CI, 4.16-7.03; I2 = 93.6%), hip BMD (WMD, 4.80; 95% CI, 2.93 to 6.66; I2 = 97.1%), total body BMD (WMD, 3.24; 95% CI, 2.12-4.35; I2 = 90.9%), femoral neck BMD (WMD, 4.02; 95% CI, 1.70-6.35; I2 = 91.8%) and trochanter BMD (WMD, 5.22; 95% CI, 3.51-6.93; I2 = 83.6%) when compared to placebo. Zoledronate was associated with a great treatment effect on fragility fracture (RR, 0.63; 95% CI, 0.50-0.79), clinical vertebral fracture (RR, 0.41; 95% CI, 0.22-0.76), and radiographic vertebral fracture (RR, 0.60; 95% CI, 0.27-1.35) compared to placebo. Meanwhile, alendronate was also associated with beneficial effects on fragility fracture (RR, 0.40; 95% CI, 0.15-1.07), clinical vertebral fracture (RR, 0.46; 95% CI, 0.17-1.24), and radiographic vertebral fracture (RR, 0.64; 95% CI, 0.38-1.09). In addition, the use of bisphosphonates reduced the concentration of procollagen type I N-terminal propeptide (PINP) and C-terminal telopeptide of type I collagen (CTX) over placebo by 15.79 (95% CI, -18.92 to -12.66; I2 = 28.4%), -0.23 (95% CI, -0.35 to -0.10; I2 = 91.3%), respectively. Although there was insufficient evidence to determine their safety, these bisphosphonates may have an effect on cancer, cardiac events, and mortality in osteopenic older women. Conclusion: All bisphosphonates examined were associated with beneficial effects on fractures, BMD, and bone markers in women with osteopenia. Further randomized controlled trials are necessary to clarify the safety of bisphosphonates in women with osteopenia." @default.
• W4280492468 created "2022-05-22" @default.
• W4280492468 creator A5000216780 @default.
• W4280492468 creator A5017825677 @default.
• W4280492468 creator A5022958901 @default.
• W4280492468 creator A5035416596 @default.
• W4280492468 creator A5053456989 @default.
• W4280492468 creator A5061457765 @default.
• W4280492468 creator A5070060968 @default.
• W4280492468 date "2022-05-19" @default.
• W4280492468 modified "2023-10-18" @default.
• W4280492468 title "Effects of Bisphosphonates Treatments in Osteopenic Older Women: A Systematic Review and Meta-Analysis" @default.
• W4280492468 cites W1606867770 @default.
• W4280492468 cites W1899922422 @default.
• W4280492468 cites W1972254217 @default.
• W4280492468 cites W1980534649 @default.
• W4280492468 cites W1989730019 @default.
• W4280492468 cites W1993035292 @default.
• W4280492468 cites W1997903603 @default.
• W4280492468 cites W1999631724 @default.
• W4280492468 cites W2004424725 @default.
• W4280492468 cites W2008466579 @default.
• W4280492468 cites W2034359489 @default.
• W4280492468 cites W2039548369 @default.
• W4280492468 cites W2040645421 @default.
• W4280492468 cites W2045853612 @default.
• W4280492468 cites W2108063837 @default.
• W4280492468 cites W2116311190 @default.
• W4280492468 cites W2116605720 @default.
• W4280492468 cites W2126070576 @default.
• W4280492468 cites W2126322336 @default.
• W4280492468 cites W2134304734 @default.
• W4280492468 cites W2134833483 @default.
• W4280492468 cites W2137698323 @default.
• W4280492468 cites W2138691465 @default.
• W4280492468 cites W2155236480 @default.
• W4280492468 cites W2159339075 @default.
• W4280492468 cites W2160410818 @default.
• W4280492468 cites W2163830908 @default.
• W4280492468 cites W2317911982 @default.
• W4280492468 cites W2319566666 @default.
• W4280492468 cites W2328999459 @default.
• W4280492468 cites W2415768403 @default.
• W4280492468 cites W2472189131 @default.
• W4280492468 cites W2574774326 @default.
• W4280492468 cites W2733907025 @default.
• W4280492468 cites W2751059673 @default.
• W4280492468 cites W2893745569 @default.
• W4280492468 cites W2940460340 @default.
• W4280492468 cites W2980108101 @default.
• W4280492468 cites W2983840937 @default.
• W4280492468 cites W3032492411 @default.
• W4280492468 cites W3044275622 @default.
• W4280492468 doi "https://doi.org/10.3389/fphar.2022.892091" @default.
• W4280492468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35662708" @default.
• W4280492468 hasPublicationYear "2022" @default.
• W4280492468 type Work @default.
• W4280492468 citedByCount "4" @default.
• W4280492468 countsByYear W42804924682022 @default.
• W4280492468 countsByYear W42804924682023 @default.
• W4280492468 crossrefType "journal-article" @default.
• W4280492468 hasAuthorship W4280492468A5000216780 @default.
• W4280492468 hasAuthorship W4280492468A5017825677 @default.
• W4280492468 hasAuthorship W4280492468A5022958901 @default.
• W4280492468 hasAuthorship W4280492468A5035416596 @default.
• W4280492468 hasAuthorship W4280492468A5053456989 @default.
• W4280492468 hasAuthorship W4280492468A5061457765 @default.
• W4280492468 hasAuthorship W4280492468A5070060968 @default.
• W4280492468 hasBestOaLocation W42804924681 @default.
• W4280492468 hasConcept C126322002 @default.
• W4280492468 hasConcept C126894567 @default.
• W4280492468 hasConcept C141071460 @default.
• W4280492468 hasConcept C142724271 @default.
• W4280492468 hasConcept C168563851 @default.
• W4280492468 hasConcept C197934379 @default.
• W4280492468 hasConcept C199343813 @default.
• W4280492468 hasConcept C204787440 @default.
• W4280492468 hasConcept C27081682 @default.
• W4280492468 hasConcept C2775854910 @default.
• W4280492468 hasConcept C2776478404 @default.
• W4280492468 hasConcept C2776541429 @default.
• W4280492468 hasConcept C2776548296 @default.
• W4280492468 hasConcept C2776886416 @default.
• W4280492468 hasConcept C2779329777 @default.
• W4280492468 hasConcept C44249647 @default.
• W4280492468 hasConcept C71924100 @default.
• W4280492468 hasConcept C82789193 @default.
• W4280492468 hasConcept C95190672 @default.
• W4280492468 hasConceptScore W4280492468C126322002 @default.
• W4280492468 hasConceptScore W4280492468C126894567 @default.
• W4280492468 hasConceptScore W4280492468C141071460 @default.
• W4280492468 hasConceptScore W4280492468C142724271 @default.
• W4280492468 hasConceptScore W4280492468C168563851 @default.
• W4280492468 hasConceptScore W4280492468C197934379 @default.
• W4280492468 hasConceptScore W4280492468C199343813 @default.
• W4280492468 hasConceptScore W4280492468C204787440 @default.
• W4280492468 hasConceptScore W4280492468C27081682 @default.
• W4280492468 hasConceptScore W4280492468C2775854910 @default.
• W4280492468 hasConceptScore W4280492468C2776478404 @default.
• W4280492468 hasConceptScore W4280492468C2776541429 @default.

• next